title: Updates in the treatment of bone cancer.
abstract: Although extremely rare, primary bone cancers are often curable with proper treatment. Effective management of primary bone tumors hinges on the involvement of a multidisciplinary team of physicians with expertise in this area, both in the realms of diagnosis and treatment. In her presentation at the NCCN 18th Annual Conference, Dr. J. Sybil Biermann reviewed the changes to the 2013 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for bone cancer, featuring the introduction of new sections on giant cell tumor of bone (GCTB) and chordoma. The benefits of denosumab for the benign GCTB and the unique challenges associated with the malignant chordoma are also explored.
authors.affiliation: Sarcoma Program at University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109-0946, USA. biermann@med.umich.edu
authors.forename: J Sybil
authors.initials: JS
authors.lastname: Biermann
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000175:diagnosis / Q000628:therapy*; D002817:Chordoma / Q000628:therapy; D003131:Combined Modality Therapy; D000069448:Denosumab; D018212:Giant Cell Tumor of Bone / Q000628:therapy; D006801:Humans; D017410:Practice Guidelines as Topic; D053245:RANK Ligand / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D053245:RANK Ligand; D000069448:Denosumab